Clinical Trials Logo

Clinical Trial Summary

Null hypothesis of this study: Biliary atresia patients with cholestatic jaundice do not have systemic immunity defect.


Clinical Trial Description

Biliary atresia patients with cholestatic jaundice were noted to have increased incidence of infectious complications. Previous animal models of bile duct ligation with acute jaundice ever demonstrated impairment of both humoral and cellular immune function. We performed the immunity study in biliary atresia patients due to the lack of comprehensive systemic immunity study in pediatric cholestatic model. Systemic humoral immunity (total serum IgG, IgA, IgM, C3 and C4), specific cellular immunity (lymphocyte classification, mitogen response, cytokines level after PHA stimulation test), and non-specific cellular immunity (absolute neutrophil count, PMN CD11b/CD18 expression level, PMN superoxide release function, and PMN phagocytosis function) were tested. Association with serum bilirubin level, nutritional status and blood biochemical values were tested to see the relation between systemic immune function and cholestatic jaundice. ;


Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal


Related Conditions & MeSH terms


NCT number NCT00155194
Study type Observational
Source National Taiwan University Hospital
Contact Jia-Feng Wu, MD
Phone 886-2-23123456
Email water@ha.mc.ntu.edu.tw
Status Recruiting
Phase N/A
Start date April 2004

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03667534 - Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
Completed NCT02652533 - Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
Completed NCT01443572 - The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation N/A
Recruiting NCT04373941 - Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia Phase 2
Completed NCT01854827 - Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia Phase 1/Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Recruiting NCT05848310 - Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Recruiting NCT05072626 - High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
Completed NCT02292862 - Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation N/A
Completed NCT00294684 - A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy N/A
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Recruiting NCT06184971 - Biliary Atresia Research Network Northeast
Recruiting NCT04260503 - Gut Microbiome in Biliary Atresia
Not yet recruiting NCT06260566 - Tolerability of Enteral NAC in Infants Phase 1
Completed NCT01322386 - Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Phase 1
Recruiting NCT05909033 - Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
Completed NCT03499249 - N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy Phase 2
Recruiting NCT00345553 - Biliary Atresia Study in Infants and Children
Recruiting NCT05521152 - Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Phase 3
Not yet recruiting NCT05783518 - Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients Phase 4